Literature DB >> 29391146

Ischemic Mitral Regurgitation: Abnormal Strain Overestimates Nonviable Myocardium.

Ashley E Morgan1, Yue Zhang2, Mehrzad Tartibi2, Samantha Goldburg3, Jiwon J Kim3, Thanh D Nguyen4, Julius Guccione5, Liang Ge5, Jonathan W Weinsaft3, Mark B Ratcliffe6.   

Abstract

BACKGROUND: Therapy for moderate ischemic mitral regurgitation remains unclear. Determination of myocardial viability, a necessary prerequisite for an improvement in regional contractility, is a likely key factor in determining response to revascularization alone. Myocardial strain has been proposed as a viability measure but has not been compared with late gadolinium enhancement (LGE) cardiac magnetic resonance imaging. We hypothesized that abnormal strain overestimates nonviable left ventricular (LV) segments measured with LGE and that ischemia and mechanical tethering by adjacent transmural myocardial infarction (TMI) also decreases strain in viable segments.
METHODS: Sixteen patients with mild or greater ischemic mitral regurgitation and 7 healthy volunteers underwent cardiac magnetic resonance imaging with noninvasive tags (complementary spatial modulation of magnetization [CSPAMM]), LGE, and stress perfusion. CSPAMM images were post-processed with harmonic phase and circumferential and longitudinal strains were calculated. Viability was defined as the absence of TMI on LGE (hyperenhancement >50% of wall thickness). The borderzone was defined as any segment bordering TMI. Abnormal strain thresholds (±1 to 2.5 SDs from normal mean) were compared with TMI, ischemia, and borderzone.
RESULTS: 7.4% of LV segments had TMI on LGE, and more than 14.5% of LV segments were nonviable by strain thresholds (p < 0.005). In viable segments, ischemia impaired longitudinal strain (least perfused one-third of LV segments: -0.18 ± 0.08 versus most perfused: -0.22 ± 0.1, p = 0.01) and circumferential strain (-0.12 ± 0.1 versus -0.16 ± 0.08, p < 0.05). In addition, infarct proximity impaired longitudinal strain (-0.16 ± 0.11 borderzone versus -0.18 ± 0.09 remote, p = 0.05).
CONCLUSIONS: Impaired LV strain overestimates nonviable myocardium compared with TMI on LGE. Ischemia and infarct proximity also decrease strain in viable segments.
Copyright © 2018 The Society of Thoracic Surgeons. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2018        PMID: 29391146      PMCID: PMC6005393          DOI: 10.1016/j.athoracsur.2018.01.005

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  31 in total

1.  Outcomes of the RESTOR-MV Trial (Randomized Evaluation of a Surgical Treatment for Off-Pump Repair of the Mitral Valve).

Authors:  Eugene A Grossi; Nirav Patel; Y Joseph Woo; Judith D Goldberg; Charles F Schwartz; Valavanur Subramanian; Ted Feldman; Robert Bourge; Norbert Baumgartner; Christopher Genco; Scott Goldman; Marco Zenati; J Alan Wolfe; Yugal K Mishra; Naresh Trehan; Sanjay Mittal; Shulian Shang; Todd J Mortier; Cyril J Schweich
Journal:  J Am Coll Cardiol       Date:  2010-12-07       Impact factor: 24.094

2.  Predictors of improvement of unrepaired moderate ischemic mitral regurgitation in patients undergoing elective isolated coronary artery bypass graft surgery.

Authors:  Martin Penicka; Hana Linkova; Otto Lang; Richard Fojt; Viktor Kocka; Marc Vanderheyden; Jozef Bartunek
Journal:  Circulation       Date:  2009-09-28       Impact factor: 29.690

3.  Improved myocardial tagging contrast.

Authors:  S E Fischer; G C McKinnon; S E Maier; P Boesiger
Journal:  Magn Reson Med       Date:  1993-08       Impact factor: 4.668

4.  Relationship of MRI delayed contrast enhancement to irreversible injury, infarct age, and contractile function.

Authors:  R J Kim; D S Fieno; T B Parrish; K Harris; E L Chen; O Simonetti; J Bundy; J P Finn; F J Klocke; R M Judd
Journal:  Circulation       Date:  1999-11-09       Impact factor: 29.690

5.  Myocardial viability and survival in ischemic left ventricular dysfunction.

Authors:  Robert O Bonow; Gerald Maurer; Kerry L Lee; Thomas A Holly; Philip F Binkley; Patrice Desvigne-Nickens; Jaroslaw Drozdz; Pedro S Farsky; Arthur M Feldman; Torsten Doenst; Robert E Michler; Daniel S Berman; Jose C Nicolau; Patricia A Pellikka; Krzysztof Wrobel; Nasri Alotti; Federico M Asch; Liliana E Favaloro; Lilin She; Eric J Velazquez; Robert H Jones; Julio A Panza
Journal:  N Engl J Med       Date:  2011-04-04       Impact factor: 91.245

6.  F-18-fluorodeoxyglucose positron emission tomography imaging-assisted management of patients with severe left ventricular dysfunction and suspected coronary disease: a randomized, controlled trial (PARR-2).

Authors:  Rob S B Beanlands; Graham Nichol; Ella Huszti; Dennis Humen; Normand Racine; Michael Freeman; Karen Y Gulenchyn; Linda Garrard; Robert deKemp; Ann Guo; Terrence D Ruddy; Francois Benard; André Lamy; Robert M Iwanochko
Journal:  J Am Coll Cardiol       Date:  2007-10-10       Impact factor: 24.094

Review 7.  MRI for the assessment of myocardial viability.

Authors:  Jonathan W Weinsaft; Igor Klem; Robert M Judd
Journal:  Cardiol Clin       Date:  2007-02       Impact factor: 2.213

8.  Left ventricular myocardial contractility is depressed in the borderzone after posterolateral myocardial infarction.

Authors:  Rafael Shimkunas; Zhihong Zhang; Jonathan F Wenk; Mehrdad Soleimani; Michael Khazalpour; Gabriel Acevedo-Bolton; Guanying Wang; David Saloner; Rakesh Mishra; Arthur W Wallace; Liang Ge; Anthony J Baker; Julius M Guccione; Mark B Ratcliffe
Journal:  Ann Thorac Surg       Date:  2013-03-21       Impact factor: 4.330

9.  Viability assessment with global left ventricular longitudinal strain predicts recovery of left ventricular function after acute myocardial infarction.

Authors:  Sjoerd A Mollema; Victoria Delgado; Matteo Bertini; M Louisa Antoni; Eric Boersma; Eduard R Holman; Marcel P M Stokkel; Ernst E van der Wall; Martin J Schalij; Jeroen J Bax
Journal:  Circ Cardiovasc Imaging       Date:  2009-10-09       Impact factor: 7.792

10.  Comparison of contrast-enhanced MRI with (18)F-FDG PET/201Tl SPECT in dysfunctional myocardium: relation to early functional outcome after surgical revascularization in chronic ischemic heart disease.

Authors:  Yen-Wen Wu; Eiji Tadamura; Masaki Yamamuro; Shotaro Kanao; Akira Marui; Keiichi Tanabara; Masashi Komeda; Kaori Togashi
Journal:  J Nucl Med       Date:  2007-07       Impact factor: 10.057

View more
  4 in total

1.  All Roads Lead to Rome: Diverse Etiologies of Tricuspid Regurgitation Create a Predictable Constellation of Right Ventricular Shape Changes.

Authors:  Benjamin A Orkild; Brian Zenger; Krithika Iyer; Lindsay C Rupp; Majd M Ibrahim; Atefeh G Khashani; Maura D Perez; Markus D Foote; Jake A Bergquist; Alan K Morris; Jiwon J Kim; Benjamin A Steinberg; Craig Selzman; Mark B Ratcliffe; Rob S MacLeod; Shireen Elhabian; Ashley E Morgan
Journal:  Front Physiol       Date:  2022-06-02       Impact factor: 4.755

2.  Fully automatic segmentation of 4D MRI for cardiac functional measurements.

Authors:  Yan Wang; Yue Zhang; Wanling Xuan; Evan Kao; Peng Cao; Bing Tian; Karen Ordovas; David Saloner; Jing Liu
Journal:  Med Phys       Date:  2018-11-20       Impact factor: 4.071

3.  Diagnostic performance of cardiac magnetic resonance segmental myocardial strain for detecting microvascular obstruction and late gadolinium enhancement in patients presenting after a ST-elevation myocardial infarction.

Authors:  Christoph Gräni; Anselm W Stark; Kady Fischer; Monika Fürholz; Andreas Wahl; Sophie A Erne; Adrian T Huber; Dominik P Guensch; René Vollenbroich; Andrea Ruberti; Stephan Dobner; Dik Heg; Stephan Windecker; Jonas Lanz; Thomas Pilgrim
Journal:  Front Cardiovasc Med       Date:  2022-07-14

4.  A Novel MRI-Based Finite Element Modeling Method for Calculation of Myocardial Ischemia Effect in Patients With Functional Mitral Regurgitation.

Authors:  Yue Zhang; Vicky Y Wang; Ashley E Morgan; Jiwon Kim; Liang Ge; Julius M Guccione; Jonathan W Weinsaft; Mark B Ratcliffe
Journal:  Front Physiol       Date:  2020-03-13       Impact factor: 4.566

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.